Viral Clearance: ensure the safety of biopharmaceuticals and medical devices for human use.

Viral clearance studies are required to assess the safety of biopharmaceuticals, such as blood products, monoclonal antibodies, recombinant proteins, tissue derived products, and medical devices prior to entering clinical trials and ahead of commercial launch.

Mérieux NutriSciences - Viral clearance

Raw materials of animal origin, used to obtain biopharmaceutical product and medical devices, may contain viruses dangerous to human health. The EU legislation requires manufacturers of biopharmaceutical products or medical devices to demonstrate the ability of manufacturing and purification processes to inactivate or remove viruses [EMA CPMP/BWP/268/95 (biopharmaceutical products) and ISO 22442-3 (medical devices)].

The objective of viral clearance studies is to evaluate the ability of the manufacturing process to inactivate/remove known viral contaminants, and to estimate process robustness by characterizing its ability to clear model viruses resembling virus that might be present in the raw material.

The control of biopharmaceuticals and medical devices must take place at 3 levels:

  1. selecting and testing the raw material, i.e. cell lines, tissues, organs, media components, for the absence of undesirable viruses which may be infectious and/or pathogenic for humans;
  2. assessing the capacity of the production processes to clear infectious viruses;
  3. testing the product at appropriate steps of production for the absence of contaminating infectious viruses.

 

See below the Viruses available for viral clearance study:

It is extremely important that the design, planning and execution of the viral clearance study are discussed in details with the Customer. Thanks to the wide experience of Mérieux NutriSciences Specialists, we are able to assist you from the very beginning for outlining the whole study and we will guide you through the selection of the steps to challenge for demonstrating viral clearance.

 

  • Assist you in the design of the study and the selection of the steps to challenge for demonstrating viral clearance
  • Suggest the most appropriate viruses for your purpose, chosen among more than 15 different viral strains
  • Decide with you how to perform the scaling down and which might be the most suitable quality controls to apply
  • We can implement the scaling down process according to your needs and in full autonomy (no need for one of your specialist to be on site)
  • You will have constant updates and direct contact with the specialist assigned to your study
  • We are able to rapidly answer your question and provide you with a fast execution of the study
  • We have a dedicated two room-laboratory only for Viral clearance studies
  • The facility has moreover one safety level 2 and one safety level 3 laboratories, fully equipped

You might be also interested in:

August 7th, 2019
News
according to IEC 62366-1:2015 and IECIEC/TR 62366-2:2016 One of the main reasons of medical device recalled are usability issues. Medical devices fault caused by design, packaging/labelling, user o...
July 25th, 2019
Press Release , Local News
On July 3rd 2019, Valbiotis announced positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective on people suffering from dysglycemia. We ...